The new Merck

The new merck

Following on from yesterday's reports that Merck is now the world's second-biggest drug-maker after the completion of its acquisition of rival firm Schering-Plough Corp., "New Merck" has begun operations.

In the dawning of a new era for the New Jersey-based drug-maker, Merck has this morning outlined its global plans for the new Merck. The company, now being touted as "global health care leader aimed at providing innovative, distinctive products and services" is set to deliver on their promises to save and improve lives, while satisfying customer needs and creating long-term shareholder value.

According to Richard T. Clark, chairman, president and CEO of Merck, "The new Merck is built on a foundation of scientific innovation and dedication to the well-being of patients around the world."

He added, "On 'Day One' for the new Merck, we are stronger and better equipped to make a difference in the lives of people globally through our broadened, diversified portfolio of innovative medicines and vaccines, and products for consumer and animal health.

"The combination of the considerable talents of Schering-Plough and Merck employees across the globe positions Merck to move through this dynamic time for our industry with a clear vision for the future."

Leverage

The new Merck certainly has a spring in its step. The company's portfolio of prescription medicines, vaccines and animal and consumer health products is complemented by a robust pipeline with more than 15 promising late-stage candidates spanning critical therapeutic categories.

The pharmaceutical company now also boasts approximately 106,000 employees and operates in more than 140 countries around the world - including emerging markets - with the firm expecting to generate more than 50 percent of its revenue outside the US.

What's more, by leveraging Merck's expanded product offerings, the company expects to benefit from additional revenue growth opportunities - something that has so far been highlighted by Clark's admission that Merck will now pursue expanded life-cycle management through the introduction of potential new combinations and formulations of existing products.

In his closing words to journalists yesterday, Clark explained how the people of the new Merck share a passion for the good medicines and vaccines can do for patients. "Thanks to the talent and dedication of scientists at both companies, the combined company offers an outstanding clinical development pipeline that will greatly increase our ability to deliver important new medicines to patients," he added.

Related Articles:

Merck's $3.4bn Q3 profits | Merck now second-biggest pharma firm | For Your Information

Like this article? Get the RSS feed: